Skip to main content

Table 1 Cost of providing RSV immunoprophylaxis to Infants by Risk Group (assuming 100% coverage)

From: Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? – a cost-utility analysis

Risk group

% of births

Births in 2015

Vaccination Cost USD

CHD

0.03%

50

314,057

CLD

0.12%

217

1,360,912

<29

0.42%

753

4,731,498

29–32

0.88%

1570

9,862,078

33–36

6.13%

10,956

68,814,325

No risk

92.42%

165,177

1,037,499,916